ScinoPharm Taiwan Ltd
ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, the America, and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptide… Read more
Market Cap & Net Worth: ScinoPharm Taiwan Ltd (1789)
ScinoPharm Taiwan Ltd (TW:1789) has a market capitalization of $495.91 Million (NT$16.41 Billion) as of March 18, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #15955 globally and #600 in its home market, demonstrating a 2.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ScinoPharm Taiwan Ltd's stock price NT$20.75 by its total outstanding shares 790739000 (790.74 Million).
ScinoPharm Taiwan Ltd Market Cap History: 2015 to 2026
ScinoPharm Taiwan Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.17 Billion to $495.91 Million (-4.73% CAGR).
ScinoPharm Taiwan Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ScinoPharm Taiwan Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.13x
ScinoPharm Taiwan Ltd's market cap is 0.13 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.92x
ScinoPharm Taiwan Ltd's market cap is 2.92 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $844.25 Million | $4.03 Billion | $658.69 Million | 0.21x | 1.28x |
| 2017 | $780.36 Million | $3.52 Billion | $422.37 Million | 0.22x | 1.85x |
| 2018 | $539.79 Million | $3.52 Billion | $442.98 Million | 0.15x | 1.22x |
| 2019 | $606.20 Million | $2.89 Billion | $216.66 Million | 0.21x | 2.80x |
| 2020 | $662.82 Million | $3.08 Billion | $282.07 Million | 0.21x | 2.35x |
| 2021 | $578.07 Million | $2.76 Billion | $243.47 Million | 0.21x | 2.37x |
| 2022 | $608.24 Million | $3.26 Billion | $353.22 Million | 0.19x | 1.72x |
| 2023 | $630.94 Million | $3.19 Billion | $287.06 Million | 0.20x | 2.20x |
| 2024 | $526.98 Million | $3.41 Billion | $339.35 Million | 0.15x | 1.55x |
| 2025 | $400.31 Million | $3.16 Billion | $136.95 Million | 0.13x | 2.92x |
Competitor Companies of 1789 by Market Capitalization
Companies near ScinoPharm Taiwan Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to ScinoPharm Taiwan Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
ScinoPharm Taiwan Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, ScinoPharm Taiwan Ltd's market cap moved from $1.17 Billion to $ 495.91 Million, with a yearly change of -4.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$495.91 Million | +23.88% |
| 2025 | NT$400.31 Million | -24.04% |
| 2024 | NT$526.98 Million | -16.48% |
| 2023 | NT$630.94 Million | +3.73% |
| 2022 | NT$608.24 Million | +5.22% |
| 2021 | NT$578.07 Million | -12.79% |
| 2020 | NT$662.82 Million | +9.34% |
| 2019 | NT$606.20 Million | +12.30% |
| 2018 | NT$539.79 Million | -30.83% |
| 2017 | NT$780.36 Million | -7.57% |
| 2016 | NT$844.25 Million | -27.69% |
| 2015 | NT$1.17 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of ScinoPharm Taiwan Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $495.91 Million USD |
| MoneyControl | $495.91 Million USD |
| MarketWatch | $495.91 Million USD |
| marketcap.company | $495.91 Million USD |
| Reuters | $495.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.